Iron management in chronic kidney disease: Conclusions from a "kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference

Autores
Macdougall, Iain C.; Bircher, Andreas J.; Eckardt, Kai Uwe; Obrador, Gregorio T.; Pollock, Carol A.; Stenvinkel, Peter; Swinkels, Dorine W.; Wanner, Christoph; Weiss, Günter; Chertow, Glenn M.; Toblli, Jorge Eduardo
Año de publicación
2016
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
Before the introduction of erythropoiesis-stimulating agents (ESAs) in 1989, repeated transfusions given to patients with end-stage renal disease caused iron overload, and the need for supplemental iron was rare. However, with the widespread introduction of ESAs, it was recognized that supplemental iron was necessary to optimize hemoglobin response and allow reduction of the ESA dose for economic reasons and recent concerns about ESA safety. Iron supplementation was also found to be more efficacious via intravenous compared to oral administration, and the use of intravenous iron has escalated in recent years. The safety of various iron compounds has been of theoretical concern due to their potential to induce iron overload, oxidative stress, hypersensitivity reactions, and a permissive environment for infectious processes. Therefore, an expert group was convened to assess the benefits and risks of parenteral iron, and to provide strategies for its optimal use while mitigating the risk for acute reactions and other adverse effects.
Fil: Macdougall, Iain C.. King's College Hospital Nhs Foundation Trust; Reino Unido
Fil: Bircher, Andreas J.. Universitatsspital Basel; Suiza
Fil: Eckardt, Kai Uwe. Universitat Erlangen-nuremberg; Alemania
Fil: Obrador, Gregorio T.. Universidad Panamericana; México
Fil: Pollock, Carol A.. The University Of Sydney; Australia. Royal North Shore Hospital; Australia
Fil: Stenvinkel, Peter. Karolinska University Hospital; Suecia
Fil: Swinkels, Dorine W.. Radboud University Nijmegen Medical Centre; Países Bajos
Fil: Wanner, Christoph. Universitatsklinikum Wurzburg; Alemania
Fil: Weiss, Günter. Medizinische Universitat Innsbruck; Austria
Fil: Chertow, Glenn M.. University Of Stanford; Estados Unidos
Fil: Toblli, Jorge Eduardo. Hospital Alemán. Laboratorio de Medicina Experimental; Argentina. Universidad de Buenos Aires. Facultad de Medicina; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Materia
Chronic Kidney Disease
Hypersensitivity
Infections
Iron
Overload
Oxidative Stress
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc-nd/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/17500
Acceder
id CONICETDig_fc3e7c65d158c265d6b602daa729573d
oai_identifier_str oai:ri.conicet.gov.ar:11336/17500
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Iron management in chronic kidney disease: Conclusions from a "kidney Disease: Improving Global Outcomes" (KDIGO) Controversies ConferenceMacdougall, Iain C.Bircher, Andreas J.Eckardt, Kai UweObrador, Gregorio T.Pollock, Carol A.Stenvinkel, PeterSwinkels, Dorine W.Wanner, ChristophWeiss, GünterChertow, Glenn M.Toblli, Jorge EduardoChronic Kidney DiseaseHypersensitivityInfectionsIronOverloadOxidative Stresshttps://purl.org/becyt/ford/3.2https://purl.org/becyt/ford/3Before the introduction of erythropoiesis-stimulating agents (ESAs) in 1989, repeated transfusions given to patients with end-stage renal disease caused iron overload, and the need for supplemental iron was rare. However, with the widespread introduction of ESAs, it was recognized that supplemental iron was necessary to optimize hemoglobin response and allow reduction of the ESA dose for economic reasons and recent concerns about ESA safety. Iron supplementation was also found to be more efficacious via intravenous compared to oral administration, and the use of intravenous iron has escalated in recent years. The safety of various iron compounds has been of theoretical concern due to their potential to induce iron overload, oxidative stress, hypersensitivity reactions, and a permissive environment for infectious processes. Therefore, an expert group was convened to assess the benefits and risks of parenteral iron, and to provide strategies for its optimal use while mitigating the risk for acute reactions and other adverse effects.Fil: Macdougall, Iain C.. King's College Hospital Nhs Foundation Trust; Reino UnidoFil: Bircher, Andreas J.. Universitatsspital Basel; SuizaFil: Eckardt, Kai Uwe. Universitat Erlangen-nuremberg; AlemaniaFil: Obrador, Gregorio T.. Universidad Panamericana; MéxicoFil: Pollock, Carol A.. The University Of Sydney; Australia. Royal North Shore Hospital; AustraliaFil: Stenvinkel, Peter. Karolinska University Hospital; SueciaFil: Swinkels, Dorine W.. Radboud University Nijmegen Medical Centre; Países BajosFil: Wanner, Christoph. Universitatsklinikum Wurzburg; AlemaniaFil: Weiss, Günter. Medizinische Universitat Innsbruck; AustriaFil: Chertow, Glenn M.. University Of Stanford; Estados UnidosFil: Toblli, Jorge Eduardo. Hospital Alemán. Laboratorio de Medicina Experimental; Argentina. Universidad de Buenos Aires. Facultad de Medicina; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaNature Publishing Group2016-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/17500Macdougall, Iain C.; Bircher, Andreas J.; Eckardt, Kai Uwe; Obrador, Gregorio T.; Pollock, Carol A.; et al.; Iron management in chronic kidney disease: Conclusions from a "kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference; Nature Publishing Group; Kidney International; 89; 1; 1-2016; 28-390085-2538enginfo:eu-repo/semantics/altIdentifier/doi/10.1016/j.kint.2015.10.002info:eu-repo/semantics/altIdentifier/url/http://www.sciencedirect.com/science/article/pii/S0085253815000034info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-nd/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-10T13:03:40Zoai:ri.conicet.gov.ar:11336/17500instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-10 13:03:41.242CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Iron management in chronic kidney disease: Conclusions from a "kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference
title Iron management in chronic kidney disease: Conclusions from a "kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference
spellingShingle Iron management in chronic kidney disease: Conclusions from a "kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference
Macdougall, Iain C.
Chronic Kidney Disease
Hypersensitivity
Infections
Iron
Overload
Oxidative Stress
title_short Iron management in chronic kidney disease: Conclusions from a "kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference
title_full Iron management in chronic kidney disease: Conclusions from a "kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference
title_fullStr Iron management in chronic kidney disease: Conclusions from a "kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference
title_full_unstemmed Iron management in chronic kidney disease: Conclusions from a "kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference
title_sort Iron management in chronic kidney disease: Conclusions from a "kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference
dc.creator.none.fl_str_mv Macdougall, Iain C.
Bircher, Andreas J.
Eckardt, Kai Uwe
Obrador, Gregorio T.
Pollock, Carol A.
Stenvinkel, Peter
Swinkels, Dorine W.
Wanner, Christoph
Weiss, Günter
Chertow, Glenn M.
Toblli, Jorge Eduardo
author Macdougall, Iain C.
author_facet Macdougall, Iain C.
Bircher, Andreas J.
Eckardt, Kai Uwe
Obrador, Gregorio T.
Pollock, Carol A.
Stenvinkel, Peter
Swinkels, Dorine W.
Wanner, Christoph
Weiss, Günter
Chertow, Glenn M.
Toblli, Jorge Eduardo
author_role author
author2 Bircher, Andreas J.
Eckardt, Kai Uwe
Obrador, Gregorio T.
Pollock, Carol A.
Stenvinkel, Peter
Swinkels, Dorine W.
Wanner, Christoph
Weiss, Günter
Chertow, Glenn M.
Toblli, Jorge Eduardo
author2_role author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Chronic Kidney Disease
Hypersensitivity
Infections
Iron
Overload
Oxidative Stress
topic Chronic Kidney Disease
Hypersensitivity
Infections
Iron
Overload
Oxidative Stress
purl_subject.fl_str_mv https://purl.org/becyt/ford/3.2
https://purl.org/becyt/ford/3
dc.description.none.fl_txt_mv Before the introduction of erythropoiesis-stimulating agents (ESAs) in 1989, repeated transfusions given to patients with end-stage renal disease caused iron overload, and the need for supplemental iron was rare. However, with the widespread introduction of ESAs, it was recognized that supplemental iron was necessary to optimize hemoglobin response and allow reduction of the ESA dose for economic reasons and recent concerns about ESA safety. Iron supplementation was also found to be more efficacious via intravenous compared to oral administration, and the use of intravenous iron has escalated in recent years. The safety of various iron compounds has been of theoretical concern due to their potential to induce iron overload, oxidative stress, hypersensitivity reactions, and a permissive environment for infectious processes. Therefore, an expert group was convened to assess the benefits and risks of parenteral iron, and to provide strategies for its optimal use while mitigating the risk for acute reactions and other adverse effects.
Fil: Macdougall, Iain C.. King's College Hospital Nhs Foundation Trust; Reino Unido
Fil: Bircher, Andreas J.. Universitatsspital Basel; Suiza
Fil: Eckardt, Kai Uwe. Universitat Erlangen-nuremberg; Alemania
Fil: Obrador, Gregorio T.. Universidad Panamericana; México
Fil: Pollock, Carol A.. The University Of Sydney; Australia. Royal North Shore Hospital; Australia
Fil: Stenvinkel, Peter. Karolinska University Hospital; Suecia
Fil: Swinkels, Dorine W.. Radboud University Nijmegen Medical Centre; Países Bajos
Fil: Wanner, Christoph. Universitatsklinikum Wurzburg; Alemania
Fil: Weiss, Günter. Medizinische Universitat Innsbruck; Austria
Fil: Chertow, Glenn M.. University Of Stanford; Estados Unidos
Fil: Toblli, Jorge Eduardo. Hospital Alemán. Laboratorio de Medicina Experimental; Argentina. Universidad de Buenos Aires. Facultad de Medicina; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
description Before the introduction of erythropoiesis-stimulating agents (ESAs) in 1989, repeated transfusions given to patients with end-stage renal disease caused iron overload, and the need for supplemental iron was rare. However, with the widespread introduction of ESAs, it was recognized that supplemental iron was necessary to optimize hemoglobin response and allow reduction of the ESA dose for economic reasons and recent concerns about ESA safety. Iron supplementation was also found to be more efficacious via intravenous compared to oral administration, and the use of intravenous iron has escalated in recent years. The safety of various iron compounds has been of theoretical concern due to their potential to induce iron overload, oxidative stress, hypersensitivity reactions, and a permissive environment for infectious processes. Therefore, an expert group was convened to assess the benefits and risks of parenteral iron, and to provide strategies for its optimal use while mitigating the risk for acute reactions and other adverse effects.
publishDate 2016
dc.date.none.fl_str_mv 2016-01
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/17500
Macdougall, Iain C.; Bircher, Andreas J.; Eckardt, Kai Uwe; Obrador, Gregorio T.; Pollock, Carol A.; et al.; Iron management in chronic kidney disease: Conclusions from a "kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference; Nature Publishing Group; Kidney International; 89; 1; 1-2016; 28-39
0085-2538
url http://hdl.handle.net/11336/17500
identifier_str_mv Macdougall, Iain C.; Bircher, Andreas J.; Eckardt, Kai Uwe; Obrador, Gregorio T.; Pollock, Carol A.; et al.; Iron management in chronic kidney disease: Conclusions from a "kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference; Nature Publishing Group; Kidney International; 89; 1; 1-2016; 28-39
0085-2538
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/doi/10.1016/j.kint.2015.10.002
info:eu-repo/semantics/altIdentifier/url/http://www.sciencedirect.com/science/article/pii/S0085253815000034
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-nd/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-nd/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv Nature Publishing Group
publisher.none.fl_str_mv Nature Publishing Group
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1842980100294836224
score 12.993085

Publicaciones similares